Drug-device combination developer SteadyMed Therapeutics prices its initial public offering well under range, raising $40 million instead of the initial target of $55 million.
SteadyMed Therapeutics (NSDQ:STDY) pulled the trigger on its IPO today, pricing the $40 million offering well under range and seeing its share price drop nearly 3% in mid-day trading.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1LAkidA
Cap comentari:
Publica un comentari a l'entrada